{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:01:20Z","timestamp":1791342080882,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,6]]},"DOI":"10.7759\/cureus.13183","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T08:41:34Z","timestamp":1612773694000},"source":"Crossref","is-referenced-by-count":12,"title":["Management of West Nile Encephalitis: An Uncommon Complication of West Nile Virus"],"prefix":"10.7759","author":[{"given":"Ammar","family":"Alli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Fernando","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Atoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Atoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W","family":"Millhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"West Nile Virus. (2020). Accessed. January 29, 2021: https:\/\/www.cdc.gov\/westnile\/index.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.8042","article-title":"West Nile virus: review of the literature","volume":"310","author":"Petersen LR","year":"2013","unstructured":"Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. JAMA. 2013, 310:308-15. 10.1001\/jama.2013.8042","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.8267","article-title":"The 2012 West Nile encephalitis epidemic in Dallas, Texas","volume":"310","author":"Chung WM","year":"2013","unstructured":"Chung WM, Buseman CM, Joyner SN, Hughes SM, Fomby TB, Luby JP, Haley RW. The 2012 West Nile encephalitis epidemic in Dallas, Texas. JAMA. 2013, 310:297-307. 10.1001\/jama.2013.8267","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1086\/427945","article-title":"Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases","volume":"40","author":"Kalil AC","year":"2005","unstructured":"Kalil AC, Devetten MP, Singh S, et al.. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis. 2005, 40:764-6. 10.1086\/427945","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-229537","article-title":"West Nile encephalitis mimicking neuropsychiatric lupus in a patient with systemic lupus erythematosus","volume":"12","author":"Iyer NR","year":"2019","unstructured":"Iyer NR, McCune WJ, Wallace BI. West Nile encephalitis mimicking neuropsychiatric lupus in a patient with systemic lupus erythematosus. BMJ Case Rep. 2019, 12:229537. 10.1136\/bcr-2019-229537","journal-title":"BMJ Case Rep"},{"key":"ref6","unstructured":"Diagnostic Testing | West Nile Virus. (2018). Accessed. January 29, 2021: https:\/\/www.cdc.gov\/westnile\/healthcareproviders\/healthCareProviders-Diagnostic.html."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70030-3","article-title":"West Nile virus","volume":"6","author":"Kramer LD","year":"2007","unstructured":"Kramer LD, Li J, Shi P-Y. West Nile virus. Lancet Neurol. 2007, 6:171-81. 10.1016\/S1474-4422(07)70030-3","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3201\/eid0801.010252","article-title":"Efficacy of Interferon \u03b1-2b and ribavirin against West Nile virus in vitro","volume":"8","author":"Anderson JF","year":"2002","unstructured":"Anderson JF, Rahal JJ. Efficacy of Interferon \u03b1-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis. 2002, 8:107-8. 10.3201\/eid0801.010252","journal-title":"Emerg Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2019.197770","article-title":"Flavivirus infection-a review of immunopathogenesis, immunological response, and immunodiagnosis","volume":"274","author":"Chong HY","year":"2019","unstructured":"Chong HY, Leow CY, Abdul Majeed AB, Leow CH. Flavivirus infection-a review of immunopathogenesis, immunological response, and immunodiagnosis. Virus Res. 2019, 274:197770. 10.1016\/j.virusres.2019.197770","journal-title":"Virus Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.04.007","article-title":"A novel nucleoside analog, 1-\u03b2-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro","volume":"87","author":"McDowell M","year":"2010","unstructured":"McDowell M, Gonzales SR, Kumarapperuma SC, Jeselnik M, Arterburn JB, Hanley KA. A novel nucleoside analog, 1-\u03b2-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro. Antiviral Res. 2010, 87:78-80. 10.1016\/j.antiviral.2010.04.007","journal-title":"Antiviral Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.3.455","article-title":"Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course","volume":"27","author":"Lewis M","year":"2007","unstructured":"Lewis M, Amsden JR. Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. Pharmacotherapy. 2007, 27:455-8. 10.1592\/phco.27.3.455","journal-title":"Pharmacotherapy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1017\/S031716710005383X","article-title":"Calgary experience with West Nile virus neurological syndrome during the late summer of 2003","volume":"31","author":"Sayao A-L","year":"2004","unstructured":"Sayao A-L, Suchowersky O, Al-Khathaami A, et al.. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci. 2004, 31:194-203. 10.1017\/S031716710005383X","journal-title":"Can J Neurol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2015.30.3.343","article-title":"The first reported case of West Nile encephalitis in Korea","volume":"30","author":"Hwang J","year":"2015","unstructured":"Hwang J, Ryu H-S, Kim H, Lee S-A. The first reported case of West Nile encephalitis in Korea. J Korean Med Sci. 2015, 30:343-5. 10.3346\/jkms.2015.30.3.343","journal-title":"J Korean Med Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7394.865","article-title":"West Nile encephalitis","volume":"326","author":"Solomon T","year":"2003","unstructured":"Solomon T, Ooi MH, Beasley DWC, Mallewa M. West Nile encephalitis. BMJ. 2003, 326:865-9. 10.1136\/bmj.326.7394.865","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1086\/315847","article-title":"Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells","volume":"182","author":"Jordan I","year":"2000","unstructured":"Jordan I, Briese T, Fischer N, Lau JY-N, Lipkin WI. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis. 2000, 182:1214-7. 10.1086\/315847","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.000079","article-title":"Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis","volume":"96","author":"Srivastava R","year":"2015","unstructured":"Srivastava R, Ramakrishna C, Cantin E. Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis. J Gen Virol. 2015, 96:1347-57. 10.1099\/vir.0.000079","journal-title":"J Gen Virol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20959","article-title":"West Nile virus neuroinvasive disease","volume":"60","author":"Davis LE","year":"2006","unstructured":"Davis LE, DeBiasi R, Goade DE, et al.. West Nile virus neuroinvasive disease. Ann Neurol. 2006, 60:286-300. 10.1002\/ana.20959","journal-title":"Ann Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-18","article-title":"Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection","volume":"9","author":"Ben-Nathan D","year":"2009","unstructured":"Ben-Nathan D, Gershoni-Yahalom O, Samina I, et al.. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis. 2009, 9:18. 10.1186\/1471-2334-9-18","journal-title":"BMC Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00595.x","article-title":"West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: case report and review of the literature","volume":"13","author":"Rhee C","year":"2011","unstructured":"Rhee C, Eaton EF, Concepcion W, Blackburn BG. West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: case report and review of the literature. Transpl Infect Dis. 2011, 13:312-7. 10.1111\/j.1399-3062.2010.00595.x","journal-title":"Transpl Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000438621.81686.ab","article-title":"West Nile virus infection in kidney and pancreas transplant recipients in the Dallas-Fort Worth Metroplex during the 2012 Texas epidemic","volume":"97","author":"Yango AF","year":"2014","unstructured":"Yango AF, Fischbach BV, Levy M, et al.. West Nile virus infection in kidney and pancreas transplant recipients in the Dallas-Fort Worth Metroplex during the 2012 Texas epidemic. Transplantation. 2014, 97:953-7. 10.1097\/01.TP.0000438621.81686.ab","journal-title":"Transplantation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1086\/377172","article-title":"The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis","volume":"37","author":"Haley M","year":"2003","unstructured":"Haley M, Retter AS, Fowler D, Gea-Banacloche J, O\u2019Grady NP. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis. 2003, 37:88-90. 10.1086\/377172","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00274-06","article-title":"Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection","volume":"80","author":"Shrestha B","year":"2006","unstructured":"Shrestha B, Wang T, Samuel MA, Whitby K, Craft J, Fikrig E, Diamond MS. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol. 2006, 80:5338-48. 10.1128\/JVI.00274-06","journal-title":"J Virol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1621149","article-title":"West Nile virus vaccines - current situation and future directions","volume":"15","author":"Ulbert S","year":"2019","unstructured":"Ulbert S. West Nile virus vaccines - current situation and future directions. Hum Vaccin Immunother. 2019, 15:2337-42. 10.1080\/21645515.2019.1621149","journal-title":"Hum Vaccin Immunother"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.906309","article-title":"Current trends in West Nile virus vaccine development","volume":"13","author":"Amanna IJ","year":"2014","unstructured":"Amanna IJ, Slifka MK. Current trends in West Nile virus vaccine development. Expert Rev Vaccines. 2014, 13:589-608. 10.1586\/14760584.2014.906309","journal-title":"Expert Rev Vaccines"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1007044","article-title":"Latest developments and challenges in the diagnosis of human West Nile virus infection","volume":"13","author":"Barzon L","year":"2015","unstructured":"Barzon L, Pacenti M, Ulbert S, Pal\u00f9 G. Latest developments and challenges in the diagnosis of human West Nile virus infection. Expert Rev Anti Infect Ther. 2015, 13:327-42. 10.1586\/14787210.2015.1007044","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/v5123048","article-title":"Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus","volume":"5","author":"Dayan GH","year":"2013","unstructured":"Dayan GH, Pugachev K, Bevilacqua J, Lang J, Monath TP. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013, 5:3048-70. 10.3390\/v5123048","journal-title":"Viruses"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4\u039430 is well-tolerated and immunogenic in healthy flavivirus-na\u00efve adult volunteers","volume":"31","author":"Durbin AP","year":"2013","unstructured":"Durbin AP, Wright PF, Cox A, et al.. The live attenuated chimeric vaccine rWN\/DEN4\u039430 is well-tolerated and immunogenic in healthy flavivirus-na\u00efve adult volunteers. Vaccine. 2013, 31:10.1016\/j.vaccine.2013.07.064","journal-title":"Vaccine"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial","volume":"203","author":"Ledgerwood JE","year":"2011","unstructured":"Ledgerwood JE, Pierson TC, Hubka SA, et al.. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011, 203:1396-404. 10.1093\/infdis\/jir054","journal-title":"J Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05760-7","article-title":"Identifying risks for severity of neurological symptoms in Hungarian West Nile virus patients","volume":"21","author":"Koch M","year":"2021","unstructured":"Koch M, Pozsgai \u00c9, So\u00f3s V, et al.. Identifying risks for severity of neurological symptoms in Hungarian West Nile virus patients. BMC Infect Dis. 2021, 21:65. 10.1186\/s12879-020-05760-7","journal-title":"BMC Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-017-0500-x","article-title":"Critical West Nile neuroinvasive disease","volume":"29","author":"Hawkes MA","year":"2018","unstructured":"Hawkes MA, Carabenciov ID, Wijdicks EFM, Rabinstein AA. Critical West Nile neuroinvasive disease. Neurocrit Care. 2018, 29:47-53. 10.1007\/s12028-017-0500-x","journal-title":"Neurocrit Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/51980-management-of-west-nile-encephalitis-an-uncommon-complication-of-west-nile-virus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:47Z","timestamp":1707507227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/51980-management-of-west-nile-encephalitis-an-uncommon-complication-of-west-nile-virus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.13183","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,6]]}}}